Vertex Pharmaceuticals
VRTX
494 hedge funds and large institutions have $24.5B invested in Vertex Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 208 increasing their positions, 164 reducing their positions, and 56 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
27% more repeat investments, than reductions
Existing positions increased: 208 | Existing positions reduced: 164
1% less funds holding
Funds holding: 501 → 494 (-7)
11% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 56
14% less capital invested
Capital invested by funds: $28.5B → $24.5B (-$4B)
36% less call options, than puts
Call options by funds: $86.7M | Put options by funds: $135M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$244M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$225M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$220M |
| 4 |
FAM
Fred Alger Management
New York
|
+$211M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$199M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$356M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$195M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$143M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$132M |
| 5 |
O
OppenheimerFunds
New York
|
-$94.7M |
VRTX Hedge Fund Activity: Q3 2015 in Review
494 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2015, worth a combined $24.5B — down 14% from $28.5B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of VRTX and 50 opened new positions — a net loss of 6 holders — while 164 trimmed existing stakes and 208 added.
The largest buyer was Citadel Advisors, adding an estimated $244M. The largest seller was Jennison Associates, cutting an estimated $356M.
- 494 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2015, down from 501 in Q2 2015.
- Funds reported $24.5B of Vertex Pharmaceuticals stock for Q3 2015, down 14% quarter-over-quarter.
- 50 funds opened new Vertex Pharmaceuticals positions in Q3 2015 and 56 closed out, a net change of -6 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2015 was Citadel Advisors, an estimated $244M added.
- The largest Vertex Pharmaceuticals seller in Q3 2015 was Jennison Associates, an estimated $356M sold.
Based on aggregated 13F filings for Q3 2015.